Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VLADA GROYSMAN

Allopathic & Osteopathic Physicians Dermatology

NPI
1255545455
CMS profile
56601
Location
HOOVER, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,256.21

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,166.26 125
Education $89.95 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VLADA GROYSMAN

NPI 1255545455 · CMS profile ID 56601

Allopathic & Osteopathic Physicians / Dermatology

HOOVER, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VLADA GROYSMAN, NPI 1255545455, CMS profile ID 56601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). VLADA GROYSMAN, NPI 1255545455, CMS profile ID 56601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
VLADA GROYSMAN, NPI 1255545455, CMS profile ID 56601, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $3,256.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–126 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $11.1803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812702459 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.0903/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849568907 CMS
Amgen Inc. $17.7603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826453081 CMS
PFIZER INC. $12.6503/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832520769 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $11.5403/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851937537 CMS
AbbVie Inc. $12.9803/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794683031 CMS
Allergan, Inc. $17.3203/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792791383 CMS
MERZ NORTH AMERICA, INC. $87.3703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846672867 CMS
Allergan, Inc. $28.1503/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792791381 CMS
Lumenis, Inc $14.9703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 780079371 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.6003/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851937549 CMS
VYNE Pharmaceuticals Inc. $15.1302/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830837309 CMS
Allergan, Inc. $12.0802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792791379 CMS
Janssen Biotech, Inc. $11.0602/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788041345 CMS
MERZ NORTH AMERICA, INC. $17.9402/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846672865 CMS
PFIZER INC. $12.6902/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832499545 CMS
Allergan, Inc. $3.4202/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792791377 CMS
Allergan, Inc. $14.6902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792791375 CMS
Novartis Pharmaceuticals Corporation $24.5502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812702457 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $9.8202/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851937539 CMS
Novartis Pharmaceuticals Corporation $11.4301/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812702455 CMS
Janssen Biotech, Inc. $5.7801/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788041349 CMS
PFIZER INC. $13.0101/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832509742 CMS
AbbVie Inc. $13.7701/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794683027 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.5701/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851937547 CMS
Novartis Pharmaceuticals Corporation $24.3401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812702453 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,682.82 133
PY2020 $729.67 46
PY2021 $3,256.21 126
PY2022 $20,765.94 157
PY2023 $41,750.59 163
PY2024 $39,138.72 225
PY2025 $51,149.95 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $15,334.10 1
PY2025 Principal investigator $2,468,508.01 555
PY2024 Recipient $137,724.30 1
PY2024 Principal investigator $1,824,407.26 503
PY2023 Principal investigator $795,032.19 386
PY2022 Principal investigator $682,362.02 131
PY2021 Principal investigator $809,515.09 64
PY2020 Recipient $9,403.00 9
PY2020 Principal investigator $401,615.51 68
PY2019 Principal investigator $53,326.65 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

556 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $11,535.00 12/31/2025 Non-covered Recipient Entity
Cahaba dermatology Skin Health Center
A PHASE 3 MULTICENTER LONGTERM OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO PEDIATRIC PARTICIPANTS AGED 2 YEARS AND OLDER WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228806289
Principal investigator 1 Janssen Research & Development, LLC $14,593.00 12/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373206
Principal investigator 1 SANOFI US SERVICES INC. $13,867.90 12/22/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226158007
Principal investigator 1 SANOFI US SERVICES INC. $1,268.12 12/22/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226158011
Principal investigator 1 SANOFI US SERVICES INC. $52,153.00 12/22/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226158016
Principal investigator 1 Incyte Corporation $2,949.30 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240511049
Principal investigator 1 Incyte Corporation $1,233.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511055
Principal investigator 1 Incyte Corporation $1,750.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511080
Principal investigator 1 Incyte Corporation $1,750.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511085
Principal investigator 1 Incyte Corporation $1,792.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511089
Principal investigator 1 Incyte Corporation $2,700.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511117
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511192
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511197
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511203
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511207
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511210
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511216
Principal investigator 1 Incyte Corporation $1,658.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511221
Principal investigator 1 Incyte Corporation $182.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511229
Principal investigator 1 Incyte Corporation $1,883.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511233
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511278
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511282
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511286
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511290
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511293
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511298
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511302
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511306
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511309
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511314
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511317
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511320
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511324
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511328
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511331
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511334
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511339
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511342
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511347
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511350
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511355
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511402
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511406
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511412
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511417
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511422
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511428
Principal investigator 1 Incyte Corporation $1,706.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511434
Principal investigator 1 Incyte Corporation $2,288.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511440
Principal investigator 1 Incyte Corporation $2,288.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511445
Principal investigator 1 Incyte Corporation $2,369.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511452
Principal investigator 1 Incyte Corporation $2,369.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511457
Principal investigator 1 Incyte Corporation $2,369.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511463
Principal investigator 1 Incyte Corporation $2,369.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511471
Principal investigator 1 Incyte Corporation $355.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511477
Principal investigator 1 Incyte Corporation $2,430.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511483
Principal investigator 1 Incyte Corporation $1,343.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511813
Principal investigator 1 Incyte Corporation $1,343.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511818
Principal investigator 1 Incyte Corporation $1,424.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511826
Principal investigator 1 Incyte Corporation $1,424.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511832
Principal investigator 1 Incyte Corporation $1,424.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511837
Principal investigator 1 Incyte Corporation $1,424.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511842
Principal investigator 1 Incyte Corporation $135.00 12/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $939.90 12/17/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289880
Principal investigator 1 SANOFI US SERVICES INC. $164.88 12/08/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226158003
Principal investigator 1 Incyte Corporation $20,294.60 12/05/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511172
Principal investigator 1 ABBVIE INC. $37,323.80 12/04/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528036
Principal investigator 1 ABBVIE INC. $12,121.70 12/04/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528038
Principal investigator 1 Incyte Corporation $9,839.20 12/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511041
Principal investigator 1 Incyte Corporation $2,846.80 12/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240511045
Principal investigator 1 Incyte Corporation $10,244.00 12/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511058
Principal investigator 1 Incyte Corporation $2,124.00 12/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511063
Principal investigator 1 Incyte Corporation $3,375.00 12/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511225
Principal investigator 1 Incyte Corporation $154.00 12/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511362
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,669.50 12/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289017
Principal investigator 1 ABBVIE INC. $62.50 11/26/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525450
Principal investigator 1 Incyte Corporation $3,267.00 11/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511032
Principal investigator 1 Incyte Corporation $1,976.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511109
Principal investigator 1 Incyte Corporation $1,976.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511114
Principal investigator 1 Incyte Corporation $1,885.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511122
Principal investigator 1 Incyte Corporation $1,885.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511124
Principal investigator 1 Incyte Corporation $1,885.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511127
Principal investigator 1 Incyte Corporation $1,885.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511130
Principal investigator 1 Incyte Corporation $1,885.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511134
Principal investigator 1 Incyte Corporation $1,841.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511138
Principal investigator 1 Incyte Corporation $1,841.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511143
Principal investigator 1 Incyte Corporation $1,841.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511147
Principal investigator 1 Incyte Corporation $1,539.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511152
Principal investigator 1 Incyte Corporation $1,793.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511160
Principal investigator 1 Incyte Corporation $1,793.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511163
Principal investigator 1 Incyte Corporation $1,793.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511168
Principal investigator 1 Incyte Corporation $135.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511237
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511494
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511500
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511505
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511511
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511516
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511522
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511528
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511536
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511542
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511548
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511553
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511558
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511564
Principal investigator 1 Incyte Corporation $1,559.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511595
Principal investigator 1 Incyte Corporation $1,559.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511601
Principal investigator 1 Incyte Corporation $1,559.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511606
Principal investigator 1 Incyte Corporation $1,559.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511612
Principal investigator 1 Incyte Corporation $1,305.00 11/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511618
Principal investigator 1 ABBVIE INC. $62.61 11/20/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525014
Principal investigator 1 Incyte Corporation $723.60 11/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511023
Principal investigator 1 PFIZER INC. $1,525.31 11/18/2025 Non-covered Recipient Entity
Cahaba Dermatology Skin Health Center LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228806284
Principal investigator 1 Incyte Corporation $1,233.00 11/14/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511018
Principal investigator 1 ABBVIE INC. $445.90 11/12/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523905
Principal investigator 1 Incyte Corporation $387.00 11/12/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511625
Principal investigator 1 Incyte Corporation $361.80 11/07/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511026
Principal investigator 1 Incyte Corporation $1,446.30 11/07/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240511037
Principal investigator 1 ABBVIE INC. $5,200.00 11/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523217
Principal investigator 1 ABBVIE INC. $110.50 11/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523219
Principal investigator 1 ABBVIE INC. $7,500.00 11/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202523533
Principal investigator 1 ABBVIE INC. $21,579.50 11/05/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,420.10 11/05/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288065
Principal investigator 1 ABBVIE INC. $12,519.70 11/04/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520173
Principal investigator 1 SANOFI US SERVICES INC. $900.00 11/04/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157993
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,500.00 10/27/2025 Non-covered Recipient Entity
Cahaba Dermatology and Skin Health Center LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163720
Principal investigator 1 SANOFI US SERVICES INC. $38,931.00 10/27/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157980
Principal investigator 1 Incyte Corporation $3,375.00 10/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511274
Principal investigator 1 Incyte Corporation $1,322.10 10/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511395
Principal investigator 1 Janssen Research & Development, LLC $10,175.00 10/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373200
Principal investigator 1 Janssen Research & Development, LLC $420.00 10/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373214
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 10/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287657
Principal investigator 1 Incyte Corporation $1,504.80 10/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510994
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511067
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511072
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511077
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511093
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511097
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511101
Principal investigator 1 Incyte Corporation $1,793.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511105
Principal investigator 1 Incyte Corporation $42.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511242
Principal investigator 1 Incyte Corporation $54.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511247
Principal investigator 1 Incyte Corporation $135.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511250
Principal investigator 1 Incyte Corporation $135.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511254
Principal investigator 1 Incyte Corporation $135.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511258
Principal investigator 1 Incyte Corporation $135.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511262
Principal investigator 1 Incyte Corporation $135.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511266
Principal investigator 1 Incyte Corporation $135.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511270
Principal investigator 1 Incyte Corporation $1,841.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511367
Principal investigator 1 Incyte Corporation $1,841.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511373
Principal investigator 1 Incyte Corporation $1,841.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511377
Principal investigator 1 Incyte Corporation $1,841.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511384
Principal investigator 1 Incyte Corporation $1,841.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511390
Principal investigator 1 Incyte Corporation $2,369.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511488
Principal investigator 1 Incyte Corporation $1,885.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511570
Principal investigator 1 Incyte Corporation $1,885.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511576
Principal investigator 1 Incyte Corporation $1,885.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511582
Principal investigator 1 Incyte Corporation $1,885.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511588
Principal investigator 1 Incyte Corporation $1,539.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511631
Principal investigator 1 Incyte Corporation $2,724.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511637
Principal investigator 1 Incyte Corporation $2,724.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511644
Principal investigator 1 Incyte Corporation $2,724.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511650
Principal investigator 1 Incyte Corporation $2,724.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511655
Principal investigator 1 Incyte Corporation $2,724.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511663
Principal investigator 1 Incyte Corporation $1,166.70 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511669
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511676
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511681
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511687
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511692
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511697
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511704
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511712
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511716
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511721
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511726
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511732
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511738
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511744
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511749
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511758
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511765
Principal investigator 1 Incyte Corporation $1,976.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511771
Principal investigator 1 Incyte Corporation $1,976.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511778
Principal investigator 1 Incyte Corporation $1,976.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511784
Principal investigator 1 Incyte Corporation $1,976.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511790
Principal investigator 1 Incyte Corporation $1,976.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511795
Principal investigator 1 Incyte Corporation $1,976.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511802
Principal investigator 1 Incyte Corporation $1,559.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240511806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287171
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,695.90 10/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287255
Principal investigator 1 ABBVIE INC. $42.90 10/21/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202517495
Principal investigator 1 ABBVIE INC. $42.90 10/21/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202517523
Principal investigator 1 ABBVIE INC. $9,894.30 10/21/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517525
Principal investigator 1 Janssen Research & Development, LLC $13,550.00 10/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373165
Principal investigator 1 Janssen Research & Development, LLC $116.00 10/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373182
Principal investigator 1 Janssen Research & Development, LLC $10,195.00 10/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373221
Principal investigator 1 Incyte Corporation $1,233.00 10/16/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510998
Principal investigator 1 Incyte Corporation $5,000.00 10/16/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240511015
Principal investigator 1 Eli Lilly and Company $12,530.00 10/15/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187876205
Principal investigator 1 SANOFI US SERVICES INC. $455.36 10/14/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157973
Principal investigator 1 SANOFI US SERVICES INC. $1,400.00 10/14/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157977
Principal investigator 1 ABBVIE INC. $5,620.80 10/09/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202514421
Principal investigator 1 ABBVIE INC. $21,559.90 10/09/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514423
Principal investigator 1 Incyte Corporation $1,233.00 10/09/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511007
Principal investigator 1 Incyte Corporation $1,525.50 10/09/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240511011
Principal investigator 1 Janssen Research & Development, LLC $1,680.00 10/06/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373142
Principal investigator 1 Incyte Corporation $1,979.10 10/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240511002
Principal investigator 1 Incyte Corporation $1.96 10/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511155
Principal investigator 1 Incyte Corporation $7.63 10/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511176
Principal investigator 1 Incyte Corporation $7.63 10/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511179
Principal investigator 1 Incyte Corporation $7.63 10/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511184
Principal investigator 1 Incyte Corporation $7.63 10/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511189
Principal investigator 1 Incyte Corporation $57.85 10/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240511846
Principal investigator 1 Janssen Research & Development, LLC $8,343.00 09/29/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373150
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,408.20 09/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285981
Principal investigator 1 Incyte Corporation $42.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510709
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510714
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510717
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510721
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510724
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510729
Principal investigator 1 Incyte Corporation $1,885.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510733
Principal investigator 1 Incyte Corporation $1,885.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510735
Principal investigator 1 Incyte Corporation $46.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510739
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510744
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510748
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510752
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510756
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510760
Principal investigator 1 Incyte Corporation $1,885.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510764
Principal investigator 1 Incyte Corporation $1,885.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510769
Principal investigator 1 Incyte Corporation $46.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510774
Principal investigator 1 Incyte Corporation $46.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510778
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510781
Principal investigator 1 Incyte Corporation $216.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510787
Principal investigator 1 Incyte Corporation $81.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510792
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510797
Principal investigator 1 Incyte Corporation $1,885.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510801
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510804
Principal investigator 1 Incyte Corporation $1,976.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510808
Principal investigator 1 Incyte Corporation $216.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510813
Principal investigator 1 Incyte Corporation $81.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510817
Principal investigator 1 Incyte Corporation $81.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510820
Principal investigator 1 Incyte Corporation $1,841.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510824
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510830
Principal investigator 1 Incyte Corporation $1,885.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510834
Principal investigator 1 Incyte Corporation $1,793.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510867
Principal investigator 1 Incyte Corporation $1,793.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510872
Principal investigator 1 Incyte Corporation $1,793.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510876
Principal investigator 1 Incyte Corporation $1,793.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510880
Principal investigator 1 Incyte Corporation $1,793.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510911
Principal investigator 1 Incyte Corporation $1,793.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510916
Principal investigator 1 Incyte Corporation $241.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510920
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510924
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510928
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510932
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510937
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510943
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510948
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510953
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510957
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510962
Principal investigator 1 Incyte Corporation $2,724.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510965
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510980
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510984
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510986
Principal investigator 1 Incyte Corporation $135.00 09/25/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510990
Principal investigator 1 Incyte Corporation $4,592.70 09/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510646
Principal investigator 1 ABBVIE INC. $4,483.70 09/18/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511572
Principal investigator 1 Incyte Corporation $1,143.00 09/18/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510639
Principal investigator 1 Incyte Corporation $3,958.20 09/18/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510650
Principal investigator 1 Incyte Corporation $3,699.00 09/12/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510642
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,828.95 09/11/2025 Non-covered Recipient Entity
Cahaba Dermatology and Skin Health Center LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163718
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,112.50 09/10/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 09/10/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285229
Principal investigator 1 Janssen Research & Development, LLC $10,129.00 09/08/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373174
Principal investigator 1 SANOFI US SERVICES INC. $700.00 09/08/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157951
Principal investigator 1 SANOFI US SERVICES INC. $220.00 09/08/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157957
Principal investigator 1 SANOFI US SERVICES INC. $9,500.00 09/08/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157960
Principal investigator 1 SANOFI US SERVICES INC. $49,853.00 09/08/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157968
Principal investigator 1 ABBVIE INC. $28,124.60 09/04/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509826
Principal investigator 1 Incyte Corporation $1,446.30 09/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510654
Principal investigator 1 ABBVIE INC. $2,910.50 09/03/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508248
Principal investigator 1 Incyte Corporation $2,835.00 09/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510838
Principal investigator 1 SANOFI US SERVICES INC. $9,620.00 09/03/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157948
Principal investigator 1 SANOFI US SERVICES INC. $2,240.00 09/03/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157964
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 09/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 09/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 09/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285023
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,808.40 09/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285035
Principal investigator 1 Incyte Corporation $11.45 09/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510863
Principal investigator 1 Incyte Corporation $700.00 08/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510609
Principal investigator 1 Incyte Corporation $1,325.70 08/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510613
Principal investigator 1 Incyte Corporation $1,500.00 08/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510617
Principal investigator 1 Incyte Corporation $1,500.00 08/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510620
Principal investigator 1 Incyte Corporation $8,000.00 08/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510624
Principal investigator 1 Incyte Corporation $6,502.50 08/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510635
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510658
Principal investigator 1 Incyte Corporation $93.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510664
Principal investigator 1 Incyte Corporation $93.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510668
Principal investigator 1 Incyte Corporation $314.70 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510672
Principal investigator 1 Incyte Corporation $1,793.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510677
Principal investigator 1 Incyte Corporation $93.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510681
Principal investigator 1 Incyte Corporation $93.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510685
Principal investigator 1 Incyte Corporation $2,724.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510690
Principal investigator 1 Incyte Corporation $2,724.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510694
Principal investigator 1 Incyte Corporation $1,793.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510697
Principal investigator 1 Incyte Corporation $1,976.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510701
Principal investigator 1 Incyte Corporation $1,976.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510704
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510884
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510888
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510892
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510896
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510900
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510904
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510968
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510972
Principal investigator 1 Incyte Corporation $46.00 08/20/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510977
Principal investigator 1 SANOFI US SERVICES INC. $3,625.00 08/18/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157935
Principal investigator 1 SANOFI US SERVICES INC. $21,719.00 08/18/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157944
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,074.15 08/15/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284349
Principal investigator 1 Incyte Corporation $92.00 08/14/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240510907
Principal investigator 1 SANOFI US SERVICES INC. $20,482.00 08/11/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157938
Principal investigator 1 SANOFI US SERVICES INC. $5,060.40 08/11/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157940
Principal investigator 1 Arcutis Biotherapeutics, Inc. $13,763.93 08/07/2025 Non-covered Recipient Entity
Cahaba Dermatology and Skin Health Center LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163716
Principal investigator 1 Incyte Corporation $1,143.00 08/07/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510628
Principal investigator 1 Incyte Corporation $1,224.90 08/07/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510632
Principal investigator 1 Janssen Research & Development, LLC $22,900.00 08/07/2025 Non-covered Recipient Entity
Cahaba Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175163008
Principal investigator 1 ABBVIE INC. $29,825.00 08/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503361
Principal investigator 1 ABBVIE INC. $8,681.88 08/05/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202502038
Principal investigator 1 Incyte Corporation $1,500.00 08/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510846
Principal investigator 1 Incyte Corporation $8,000.00 08/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510855
Principal investigator 1 Amgen Inc. $7,500.00 08/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246639841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,233.35 08/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,309.10 08/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283651
Principal investigator 1 ABBVIE INC. $1,440.00 07/31/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202500736
Principal investigator 1 Janssen Research & Development, LLC $22,645.00 07/31/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373159
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 07/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282980
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 07/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282982
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,282.20 07/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283026
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,514.20 07/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283060
Principal investigator 1 Incyte Corporation $3,628.80 07/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510587
Principal investigator 1 Incyte Corporation $4,775.40 07/17/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510590
Principal investigator 1 Incyte Corporation $2,109.60 07/17/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510604
Principal investigator 1 Incyte Corporation $1,602.50 07/16/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510842
Principal investigator 1 Incyte Corporation $1,417.00 07/16/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510851
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,081.68 07/15/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304177
Principal investigator 1 SANOFI US SERVICES INC. $53,114.00 07/14/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157925
Principal investigator 1 PFIZER INC. $11,535.00 07/11/2025 Non-covered Recipient Entity
Cahaba Dermatology Skin Health Center LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228845659
Principal investigator 1 Incyte Corporation $361.80 07/10/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510599
Principal investigator 1 Incyte Corporation $1,233.00 07/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510594
Principal investigator 1 ABBVIE INC. $5,568.90 07/02/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495881
Principal investigator 1 ABBVIE INC. $31,811.90 07/02/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495883
Principal investigator 1 SANOFI US SERVICES INC. $9,336.00 07/02/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157922
Principal investigator 1 Incyte Corporation $54.90 07/01/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510859
Principal investigator 1 Incyte Corporation $9,495.90 06/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510557
Recipient Nielsen BioSciences, Inc. $15,334.10 06/24/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1215535990
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,000.00 06/24/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY SKIN HEALTH CENTER LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190312439
Principal investigator 1 Arcutis Biotherapeutics, Inc. $8,000.00 06/23/2025 Non-covered Recipient Entity
Cahaba Dermatology and Skin Health Center LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163714
Principal investigator 1 Janssen Research & Development, LLC $16,126.00 06/23/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175373192
Principal investigator 1 Incyte Corporation $361.80 06/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510544
Principal investigator 1 Incyte Corporation $7,012.80 06/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510561
Principal investigator 1 Incyte Corporation $1,275.30 06/18/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,717.40 06/18/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223281608
Principal investigator 1 SANOFI US SERVICES INC. $28,279.00 06/16/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157913
Principal investigator 1 Janssen Research & Development, LLC $3,845.00 06/13/2025 Non-covered Recipient Entity
Cahaba Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175162747
Principal investigator 1 Incyte Corporation $36,898.80 06/12/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510549
Principal investigator 1 Incyte Corporation $427.50 06/05/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,411.10 06/04/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280730
Principal investigator 1 ABBVIE INC. $2,754.70 06/03/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487669
Principal investigator 1 ABBVIE INC. $1,589.20 06/03/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202487685
Principal investigator 1 SANOFI US SERVICES INC. $7,430.00 05/27/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157910
Principal investigator 1 Incyte Corporation $4,491.00 05/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240510540
Principal investigator 1 SANOFI US SERVICES INC. $35,942.00 05/19/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157918
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,630.45 05/16/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279924
Principal investigator 1 Incyte Corporation $1,317.60 05/12/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510583
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162725
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162733
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162738
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162770
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162801
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162827
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162920
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162944
Principal investigator 1 Janssen Research & Development, LLC $5,544.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163049
Principal investigator 1 Janssen Research & Development, LLC $5,544.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163066
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163072
Principal investigator 1 Janssen Research & Development, LLC $5,544.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163144
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 05/08/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163379
Principal investigator 1 ABBVIE INC. $52,485.80 05/07/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483879
Principal investigator 1 ABBVIE INC. $1,309.00 05/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482135
Principal investigator 1 Incyte Corporation $1,386.90 04/14/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510578
Principal investigator 1 SANOFI US SERVICES INC. $8,449.20 04/14/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157875
Principal investigator 1 SANOFI US SERVICES INC. $93,515.00 04/14/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,607.30 04/11/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277980
Principal investigator 1 Incyte Corporation $361.80 04/07/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240510534
Principal investigator 1 ABBVIE INC. $7,161.40 04/03/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202469907
Principal investigator 1 ABBVIE INC. $12,233.50 04/03/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202469912
Principal investigator 1 Incyte Corporation $42.24 04/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510569
Principal investigator 1 Incyte Corporation $99.12 04/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510573
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,590.85 04/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277496
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,540.14 03/31/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190304171
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 03/24/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163136
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 03/24/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163160
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 03/24/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163185
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 03/24/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163241
Principal investigator 1 SANOFI US SERVICES INC. $18,164.00 03/24/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157872
Principal investigator 1 Janssen Research & Development, LLC $3,850.00 03/21/2025 Non-covered Recipient Entity
Cahaba Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175162711
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $370.00 03/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276815
Principal investigator 1 Incyte Corporation $1,180.70 03/14/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510484
Principal investigator 1 Incyte Corporation $2,062.00 03/14/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $315.00 03/12/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276321
Principal investigator 1 SANOFI US SERVICES INC. $12,450.00 03/10/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157865
Principal investigator 1 ABBVIE INC. $19,072.40 03/07/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460991
Principal investigator 1 ABBVIE INC. $1,505.20 03/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457914
Principal investigator 1 Incyte Corporation $9.80 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510487
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510499
Principal investigator 1 Incyte Corporation $15.26 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510503
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510507
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510511
Principal investigator 1 Incyte Corporation $115.70 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510515
Principal investigator 1 Incyte Corporation $15.26 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510521
Principal investigator 1 Incyte Corporation $15.26 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510525
Principal investigator 1 Incyte Corporation $15.26 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510530
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 03/03/2025 Non-covered Recipient Entity
Cahaba Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175163301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,118.20 03/03/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275863
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 02/27/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163514
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,800.00 02/27/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY SKIN HEALTH CENTER LLC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190312441
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,682.30 02/26/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275561
Principal investigator 1 SANOFI US SERVICES INC. $45,291.00 02/24/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 02/21/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275435
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162633
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162642
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162652
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162658
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162666
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162677
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162685
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162693
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162701
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162718
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162756
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162762
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162778
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162785
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162791
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162809
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162818
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162834
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162843
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162852
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162862
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162870
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162878
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162886
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162894
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162906
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162913
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162928
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162937
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162952
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162959
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162973
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162978
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162986
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162994
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162999
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163020
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163027
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163034
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163042
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163058
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163081
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163086
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163093
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163099
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163110
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163117
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163126
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163152
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163170
Principal investigator 1 Janssen Research & Development, LLC $201.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163178
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163193
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163200
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163207
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163214
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163223
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163233
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163250
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163258
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163266
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163272
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163277
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163286
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163293
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163307
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163316
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163324
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163336
Principal investigator 1 Janssen Research & Development, LLC $201.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163341
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163350
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163359
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163364
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163372
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163388
Principal investigator 1 Janssen Research & Development, LLC $201.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163396
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163404
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163413
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163427
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163435
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163444
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163452
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163461
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163478
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163483
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163491
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163499
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163506
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163521
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163529
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163537
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163556
Principal investigator 1 Janssen Research & Development, LLC $1,551.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163563
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163571
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163580
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163588
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163597
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163605
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 02/20/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163613
Principal investigator 1 Incyte Corporation $2,062.00 02/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510455
Principal investigator 1 Incyte Corporation $1,192.40 02/19/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510460
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,318.33 02/10/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190304175
Principal investigator 1 ABBVIE INC. $23,471.60 02/06/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448835
Principal investigator 1 ABBVIE INC. $1,276.50 02/05/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202445377
Principal investigator 1 SANOFI US SERVICES INC. $27,806.20 02/04/2025 Non-covered Recipient Entity
Cahaba Dermatology And Skin Health Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157861
Principal investigator 1 Eli Lilly and Company $160,974.24 01/29/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187877253
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 01/29/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162965
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 01/29/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163421
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 01/29/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163470
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 01/29/2025 Non-covered Recipient Entity
Cahaba Derm and Skin Hlth Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175163548
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $29,079.70 01/22/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274425
Principal investigator 1 Incyte Corporation $1,353.90 01/17/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510450
Principal investigator 1 Incyte Corporation $1,554.00 01/17/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510470
Principal investigator 1 Novartis Pharmaceuticals Corporation $135.48 01/15/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190304173
Principal investigator 1 Arcutis Biotherapeutics, Inc. $24,678.06 01/07/2025 Non-covered Recipient Entity
Cahaba Dermatology & Skin Health Center -S
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1248163712
Principal investigator 1 Incyte Corporation $5,684.40 01/07/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511858
Principal investigator 1 ABBVIE INC. $3,728.20 01/02/2025 Non-covered Recipient Entity
CAHABA DERM & SKIN HEALTH CTR LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202435236
Principal investigator 1 Amgen Inc. $78,859.23 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639843
Principal investigator 1 Incyte Corporation $115.62 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510463
Principal investigator 1 Incyte Corporation $40.32 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510466
Principal investigator 1 Incyte Corporation $134.40 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510475
Principal investigator 1 Incyte Corporation $148.68 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510479
Principal investigator 1 Incyte Corporation $3.93 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510491
Principal investigator 1 Incyte Corporation $545.16 01/02/2025 Non-covered Recipient Entity
CAHABA DERMATOLOGY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240510495